Arvinas, Inc. · NASDAQ:ARVN
Arvinas — Corporate Update (October 2020)
6 slides from Arvinas's corporate update, Oct 14, 2020
Slide 1: Introducing five targets for which PROTAC degraders have high potential to differentiate
1 Today: Introducing five targets for which PROTAC® protein degraders have high potential to differentiate from other drug modalities KRAS Oncogenic cell growth regulator BCL6 Transcription factor implicated in B cell lymphomas Myc Oncogenic transcription factor driving tumor cell proliferation HPK1
Slide 2: BCL6 program: oral, best-in-class targeted therapy for B-cell malignancies
Most B cell lymphomas are dependent on constitutive or deregulated expression of BCL6, a transcriptional repressor of: Cell cycle checkpoints Terminal differentiation Apoptosis DNA damage response PROTAC® degradation would address the scaffolding function of BCL6 2 Arvinas’ BCL6 program is aiming fo
Slide 3: We are taking a comprehensive approach to degrading KRAS
3 We are taking a comprehensive approach to degrading KRAS KRAS is the most frequently mutated gene in human cancer and is a classic “undruggable” target due to its lack of deep “pockets” We are creating pan-KRAS mutant, in addition to mutant-specific (e.g., G12D and G12V), degraders As a proof of c
Slide 4: Arvinas' current pipeline spans validated and undruggable targets in oncology, I-O, and neuroscience
Neuroscience Oncology / Immuno-oncology ARVN Program Research IND Enabling Phase 1 Phase 2/3 Exploratory 4 Arvinas’ current pipeline encompasses a range of validated and undruggable targets in oncology, I-O, and neuroscience Indication IND 2021 IND 2022 IND 2023 IND 2022 Programs introduced today IN
Slide 5: Over the next two years, we anticipate a rapid pace of milestones
Program update Initiation of Phase 2 Completed Phase 1 data Phase 2 interim data Initiation of combination study Full Phase 2 data Combination study data ARV-110 (mCRPC) Interim Phase 1 data Initiation of combination study with CDK4/6i Completed Phase 1 data Initiation of Phase 2 CDK4/6i combination
Slide 6: Arvinas 2024 Vision: Ascending to new heights in bringing the benefits of PROTAC degraders to patients
Arvinas 2024 Vision: Ascending to new heights in bringing the benefits of PROTAC® degraders to patients Built Arvinas’ Foundation as a Pioneer in Protein Degradation Proved the Concept of Our PROTAC® Discovery Engine 2013-2018 2019-2020 2024 Vision Integrated biotech poised for launch First PROTAC®